Onconova Therapeutics Announces Upcoming Presentation at the 3rd Annual RAS Targeted Drug Development Summit
Onconova Therapeutics (NASDAQ: ONTX) announced a presentation scheduled for September 22, 2021, at the Annual RAS Targeted Drug Development Summit. The presentation will showcase data from a Phase 1/2a investigator-initiated study exploring the combination of rigosertib and nivolumab in patients with KRAS mutated non-small cell lung cancer (NSCLC). Dr. Rajwanth Veluswamy from the Icahn School of Medicine will lead the presentation titled 'Phase 1 Clinical Trial Updates for Oral Rigosertib & PD-1 Inhibitor in KRAS-mutated NSCLC,' highlighting important findings in cancer treatment.
- None.
- None.
Presentation to feature data from the Phase 1/2a investigator-initiated study of rigosertib-nivolumab combination in KRAS mutated non-small cell lung cancer
NEWTOWN, Pa., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced an upcoming presentation at the 3rd Annual RAS Targeted Drug Development Summit that will feature data from a Phase 1/2a investigator-initiated study evaluating rigosertib in combination with nivolumab in advanced KRAS mutated (KRAS+) non-small cell lung cancer (NSCLC).
Details on the presentation are shown below.
| Track: | Advancing Translation & Clinical Development |
| Session Title: | Evaluating the Landscape of Clinical Trials – Successes, Insights & Learnings |
| Presentation Date: | September 22, 2021 |
| Presentation Time: | 11:30 a.m. ET |
| Presentation Title: | Phase 1 Clinical Trial Updates for Oral Rigosertib & PD-1 Inhibitor in KRAS-mutated NSCLC |
| Presenter: | Rajwanth Veluswamy, MD, MSCR, Assistant Professor, Medicine, Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai |
Those interested in registering for the summit can do so here.
About Onconova Therapeutics, Inc.
Onconova Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer. The Company has proprietary targeted anti-cancer agents designed to disrupt specific cellular pathways that are important for cancer cell proliferation.
Onconova’s novel, proprietary multi-kinase inhibitor ON 123300 is being evaluated in two separate and complementary Phase 1 dose-escalation and expansion studies. These trials are currently underway in the United States and China.
Onconova’s product candidate rigosertib is being studied in an investigator-initiated study program, including in a dose-escalation and expansion Phase 1/2a investigator-initiated study with oral rigosertib in combination with nivolumab for patients with KRAS+ non-small cell lung cancer.
For more information, please visit www.onconova.com.
Forward-Looking Statements
Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, and involve risks and uncertainties. These statements relate to Onconova’s expectations regarding the timing of Onconova’s and investigator-initiated clinical development and data presentation plans, and the mechanisms and indications for Onconova’s product candidates. Onconova has attempted to identify forward-looking statements by terminology including "believes," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should," “preliminary,” "approximately" or other words that convey uncertainty of future events or outcomes. Although Onconova believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including the success and timing of Onconova's clinical trials, investigator-initiated trials and regulatory agency and institutional review board approvals of protocols, Onconova’s collaborations, the timing of the Company’s annual stockholder meeting, market conditions and those discussed under the heading "Risk Factors" in Onconova's most recent Annual Report on Form 10-K and quarterly reports on Form 10-Q. Any forward-looking statements contained in this release speak only as of its date. Onconova undertakes no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.
Company Contact:
Avi Oler
Onconova Therapeutics, Inc.
267-759-3680
ir@onconova.us
https://www.onconova.com/contact/
Investor Contact:
Bruce Mackle
LifeSci Advisors, LLC
646-889-1200
bmackle@lifesciadvisors.com
FAQ
What is Onconova Therapeutics presenting at the September 22, 2021 summit?
Who is presenting Onconova's data on September 22, 2021?
What is the focus of the Onconova study being presented at the summit?
When is the presentation regarding rigosertib scheduled?
What is the significance of the rigosertib-nivolumab study?
